Ruxoprubart
Based on 1 Customer Validation
Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.541%
- CAS No.: 2842046-67-5
- Masse moléculaire:145.982 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Human IgG1 kappa
Human
CFB
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
AAH04143.1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
-
Immobilized Complement Factor B/CFB Protein, Human (HEK293, His, HY-P7813) can bind Ruxoprubart. The EC50 for this effect is 24.9 ng/mL.
Chemical Information
-
CAS No. 2842046-67-5
-
Appearance Liquid
-
Masse moléculaire 145.982 kDa
-
Color Colorless to light yellow
-
SMILES
[Ruxoprubart]
-
Synonyms
NM8074
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Peixoto VP, et al. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials. Curr Med Res Opin. Published online May 16, 2024. [Content Brief]
[2]. Kavanagh D, et al. Factor B as a therapeutic target for the treatment of complement-mediated diseases. Front Immunol. 2025;16:1537974. Published 2025 Feb 14. [Content Brief]
[3]. Gentile M, et al. Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review. J Clin Med. 2025;14(3):702. Published 2025 Jan 22. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Ruxoprubart
- 2842046-67-5
- NM8074
- NM 8074
- NM-8074
- Complement System
- C5 convertase
- Bb subunit
- C3b deposition
- classical complement pathway
- AP C3 convertase
- alternative complement pathway
- complement Factor B
- atypical hemolytic uremic syndrome
- paroxysmal nocturnal hemoglobinuria
- red blood cell hemolysis
- Inhibitor
- inhibitor
- inhibit